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Factor H  (fllH globulin), 1 an important control protein of the alternative pathway 
of complement  (C) activation, is recognized as having three characteristic  functions: 
(a) acceleration of the decay dissociation of the C3 convertase (C3b,Bb) by binding to 
C3b and displacing activated  factor B  (Bb)  (1);  (b)  function as an essential  cofactor 
for the cleavage inactivation of fluid-phase C3b by factor I  (C3b-inactivator)  (2); and 
(c) potentiation of the factor I cleavage of bound C3b (1).  Factor H  also binds to B 
lymphocyte membrane  receptors  that  are  specific for H  and  triggers  the  B  cells  to 
release  endogenous  factor  I  (3).  In  addition,  Hammann  and  co-workers  (4)  have 
recently reported that purified H  triggers lymphocyte blastogenesis. 
In the present  study, an antibody directed to the binding site  (idiotype)  of anti-H 
was used to characterize the structure of B cell membrane H  receptors. This strategy 
for  receptor  characterization  was  first  described  by  Sege  and  Peterson  (5),  who 
demonstrated that an antibody to the idiotype of anti-retinol-binding  protein  (RBP) 
reacted  with  prealbumin,  thus  identifying  prealbumin  as  the  probable  carrier 
("receptor") for RBP in the blood. The basis for applying this approach to H  receptor 
characterization  was  the  hypothesis  that  the  binding  site  of H  receptors  might  be 
structurally similar to the idiotype of anti-H antibody and, thus, that antibody to the 
idiotype of anti-H  might react with membrane H  receptors.  Accordingly, an anti-H 
idiotype  serum  was  prepared  by  injecting  rabbits  with  purified  goat  F(ab')2  anti- 
human  H.  Several  lines of evidence indicated  that  one of the rabbit-anti-goat-anti- 
human H  anti-idiotype antibodies (aaH) isolated from this antiserum was specific for 
human  B  cell  H  receptors.  Both actH  immunoprecipitation  and  H-agarose affinity 
chromatography  were  then  used  to  characterize  the  molecular  weight  of the  H 
receptor by sodium dodecyl sulfate-polyacrylamide gel electrophoresis  (SDS-PAGE). 
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Institutes of Health, and a grant-in-aid from the American Heart Association (80 766). 
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1  Abbreviations used  in this paper."  asH, anti-anti-H, rabbit antibody specific for the idiotype of goat-anti- 
human factor H; B, factor B; BDV, 1% BSA (bovine serum albumin) and 3.2% dextrose in 35 mM veronal 
buffer, pH  7.2, 6 mS at  22°C; BDVEA, BDV containing 20 mM EDTA and  0.2% sodium azide; C, 
complement;  C3b,  hemolytically active  fragment of C3  resulting from C  activation;  C3c and  C3d, 
fragments resulting from proteolysis  ofiC3b; CRy, C receptor type one, C4b-C3b receptor; CR2, C receptor 
type two, C3d receptor; CRa, C receptor type three, iC3b receptor; D, factor D; E, sheep erythrocytes; 
EC3b, E coated with C3b; EC3d, E coated with C3d; GVB, gelatin veronal buffer; H, factor H  (fllH 
globulin); iC3b, inactivated C3b resulting from cleavage of C3b by factor I (C3b-inaetivator); I, factor I 
(C3b-inactivator); Mg-GVB, GVB containing 5 mM MgCI~; NF, C3 nephritic factor; NP-40, Nonidet P- 
40; P, properdin; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide  gel electrophoresis. 
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Materials and Methods 
Lymphoid Cells.  The B lymphoblastoid cell  lines known as  Raji and BF, and the HSB T 
lymphoblastoid line were  maintained in RPM1  1640 media supplemented with  10%  heat- 
inactivated fetal calf serum and antibiotics. 
C Components and Sheep Erythrocyte-C3 Complexes (EC3).  Human C3, factor B (B), factor H (H), 
and factor I(I) were purified from fresh plasma, as previously described (3). Factor D (D) and 
nephritic factor (NF) were purified as described by LeSavre et al. (6) and Schreiber et al. (7). 
EC3b, containing 1.5-2.5  ×  104 molecules of C3b per cell, were prepared by addition of C3 to 
sheep E, containing the NF-stabilized C3-convertase (8), and the amount of resulting bound 
C3b was quantitated by measuring the uptake of [a2~I]monoclonal-anti-C3  (Bethesda Research 
Laboratories, Gaithersburg, MD) onto a small sample of the EC3b. A portion of the EC3b was 
converted to EC3bi and EC3d (3). 
Production of Anti-Hand aaH.  A goat was immunized intramuscularly  with weekly injections 
of 50 /xg of H  emulsified in Freund's complete adjuvant, and the plasma was  collected by 
plasmaphoresis (immunization and plasmaphoresis performed by Dr. Brian F. Tack, Harvard 
Medical School,  Boston, MA). The goat immune plasma was found to be specific  for  H  by 
Ouchterlony and immunoelectrophoretic analysis with human plasma and various purified C 
proteins. The IgG fraction of the plasma was isolated by column chromatography on DEAE- 
Sephaeel  (Pharmacia Fine Chemicals, Div.  of Pharmaeia Inc., Piscataway, N  J)  in 0.01 M 
phosphate buffer, pH 8.0, and then the F(ab')2 fragment was prepared by trypsin digestion (9) 
and column chromatography on Sephadex G-150 (Pharmaeia Fine Chemicals). The various 
different H-specific idiotypes of the F(ab')2 anti-H were then purified by absorption and 4 M 
guanidine elution from agarose containing 10 mg of bound H per ml of gel (10). Two rabbits 
were immunized weekly  at  two intramuscular sites  with  100/~g of the purified goat F(ab')2 
anti-human H emulsified in Freund's complete adjuvant over a period of 3 mo. Nonimmune 
sera was obtained before immunization, and then immune sera were collected weekly after 6 
wk of immunization. After isolation from the rabbit sera of both the nonimmune  IgG and the 
IgG aaH on DEAE-Sephaeel in 0.0175  M  phosphate buffer, pH  7.0, antibodies in the aaH 
directed to common goat IgG determinants were removed by absorption with agarose conju- 
gated (10) to the nonimmune  goat IgG obtained by absorption of the goat IgG anti-H with H- 
agarose.  A portion of the absorbed aaH was either labeled with 125I using chloramine T  (11), 
resulting in a specific activity of 6.2 ×  104 cpm//~g or, alternatively, was purified by absorption 
and 4 M  guanidine elution from either goat anti-H-agarose or C3-agarose (10 mg IgG anti-H 
or C3 per ml of gel) and then labeled with 125I (11) to a specific activity of 4-6 ×  104 cpm//~g. 
Preparation of Antibodies Specific  for CR1, CR2, C3b, and C3c.  Antibodies to CRa, CR2, and C3c 
were prepared in rabbits by immunization with the purified protein antigens (12-14). Anti- 
C3b  (kindly provided  by  Dr.  Brian  F.  Tack,  Harvard  Medical  School)  was  prepared  by 
immunization of sheep with C3b that was generated by elastase digestion of C3 and column 
chromatography on Sephadex G-200 (Pharmacia Fine Chemicals). The F(ab')2, Fab', or Fab 
fragments of these antibodies were prepared by digestion with pepsin or papain (15, 16). 
Assay for Binding of aaI-I to B Cells and C3 Fragments.  100/~1  of Raji, HSB, or BF cells at 4 × 
106 cells/ml, or alternatively E, EC3b, or EC3d at  1 ×  l0  s cells/ml, in 0.01 M  phosphate- 
buffered saline, pH 7.5, were  incubated for  15 min at 37°C with 25-/~1 volumes of increasing 
concentrations of [x25I]aaH. Each  concentration of [125I]aaH was  tested  in duplicate,  and 
controls included 125I-nonimmune  rabbit IgG, or [125I]aaH in the presence of excess unlabeled 
aaH or 1.0 mg/ml H. The quantity of bound ligand was determined after centrifugation of the 
cells in 100/~1 of suspension through 750/ll of oil at 8,000 g for 2 min (17). 
Assay for Inhibition of H Binding to B Cells and EC3b by aaI-I.  Purified H was labeled with 3H 
by reductive methylation (18) and had a  specific  activity of 3.6 ×  106 dpm//~g. The specific 
binding of [3H]H to Raji cells, BF cells, or EC3b was measured as previously described (3,  17) 
after treatment of the cells with either unlabeled H, aaH, or Fab anti-C3c. 
Assay for B Cell Release of Factor I.  The cell-free supernatants of Raji B cells incubated with 
either BDV buffer (1% bovine serum albumin (BSA) 3.2% dextrose,  in 35 mM veronal buffer, 
pH 7.2, 6 mS at 22°C) or H, aaH, and Fab anti-C3c, each diluted in BDV, were analyzed for 
their ability to convert Raji rosette-negative EC3b into Raji rosette-positive EC3bi (3). The 1402  CHARACTERIZATION OF THE  LYMPHOCYTE  FACTOR H  RECEPTOR 
specificity  of this assay for I was confirmed by demonstrating that the rosette-generating activity 
of the cell supernatants was inhibited completely by anti-I (3). 
Assay for the Factor I Cofactor Activity of Factor H and aaH.  Cleavage of 3H-labeled fluid-phase 
C3b (3) into iC3b was detected by SDS-PAGE (19), fluorography (3), and laser densitometric 
scanning of the x-ray film bands. 2.8 pg of [3H]C3b was treated with  1 /zg of I and  10/~g of 
either H or aaH in 50/zl of 30 mM NaC1 in 35 mM veronal buffer, pH 7.2, for 60 min at 37°C. 
The potentiation of I cleavage of bound C3b by H  or aaH was assessed by treating EC3b for 
30 min  at 37°C  with  H  or aaH and an  amount  of I  that  by itself produced only minimal 
amounts of bound iC3b. The formation of increased amounts of iC3b on EC3b was detected 
either by  SDS-PAGE and  fluorography analysis of EC3b  prepared with  [3H]C3  (3)  or by 
generation  of the  ability of the  treated EC3b  to  form  Raji rosettes  (3).  Controls  included 
treatment of [aH]C3b or EC3b[3H] with H, aaH, or I individually. 
Molecular Weight Analysis of B  Cell Proteins Bound by Either aaH or H.  B  cell proteins were 
intrinsically labeled by overnight culture of Raji or BF cells in media containing [3H]lucine, as 
previously described (3). For analysis of the B cell proteins reactive with aaH, the washed cells 
were solubilized with nonionic detergent (3). After removal of insoluble material by uhracen- 
trifugation  (3),  the soluble B  cell proteins from  5  ×  10  v cells in  0.5  ml  of buffer  (3)  were 
incubated with  I0/zg of either purified aaH or nonimmune rabbit IgG for 16 h at 4°C. The 
rabbit IgG and any immune complexes were then collected by centrifugation after incubation 
for 4 h at 4°C with 10/zl of agarose-anti-rabbit IgG (Miles Laboratories, Inc., Research Products 
Div., Elkhart, IN). To remove nonspecifically  bound cell proteins, the agarose-bound complexes 
were washed four times with ice-cold phosphate-buffered saline containing  1% Nonidet P40 
(NP-40)  (Particle Data  Inc., Elmhurst, IL), 0.5%  deoxycholate, 20% sucrose, 2 mM  phenyl- 
methylsulfonyl fluoride, 50  pg/ml  soybean trypsin inhibitor, 25  mM  benzamidine, 50  mM 
epsilon amino caproic acid (Sigma Chemical Co., St. Louis, MO), and  10 mM EDTA. The 
complexes were eluted from the agarose by incubation for 5 min at 100°C with 2% SDS, either 
with or without 0.1 M  dithiothreitol, and electrophoresed in 7% polyacrylamide gel slabs (19). 
The  gel  tracks  were  then  sliced  into  2-mm  segments  that  were  solubilized by  overnight 
incubation in 30% H202 at 56°C  and counted in OCS scintillation fluid (Amersham Corp., 
Arlington Heights, IL). The molecular weight of radioactive protein bands was determined 
from  their  mobility relative  to  known  molecular weight  markers  (Bio-Rad  Laboratories, 
Richmond, CA) electrophoresed in parallel gel tracks. 
For molecular weight analysis of the B cell proteins that had H-binding (H receptor) activity, 
the spent culture media from [SH]leucine intrinsically labeled Raft cells was cycled two times 
through a column containing 2 ml of either H-agarose (same as above) or control BSA-agarose 
(10 mg BSA per ml of agarose) (10) in 0.01 M phosphate-buffered saline, pH 7.5, with protease 
inhibitors (same as above). After a wash of the columns with 0.5 M  NaCI in 0.1 M  phosphate 
buffer, pH 7.5, the bound material was eluted with a mixture of 0.5% NP-40 and 0.5 M  NaC1 
in 0.1  M  phosphate buffer, pH  7.5. The eluate was dialyzed against 62.5  mM Tris/HCl, pH 
6.8, concentrated to 0.5 ml in the dialysis bag by dehydration with polyethylene glycol powder, 
treated with  2%  SDS either with or without  0.1  M  dithiothreitol for 5  min  at  100°C,  and 
electrophoresed  in  7%  polyacrylamide gel  slabs  that  were  analyzed  for  radioactivity and 
molecular weight as above. 
Results 
Characteristics  of aaH.  After absorption  with  nonimmune  goat  IgG-agarose, the 
rabbit  IgG  fraction  of  aaH  was  labeled  with  t2sI  and  analyzed  for  binding  to 
lymphocytes and EC3  (Table I). Approximately 10-fold more [lZSI]aaH was bound to 
Raji and  BF B-type lymphoblastoid cells and to EC3b  than  was bound to HSB T- 
type lymphoblastoid cells, sheep  E,  or EC3d.  By contrast,  the  labeled nonimmune 
rabbit IgG, obtained before immunization, was not bound selectively by any cell type. 
This absence of binding of nonimmune IgG indicated that Fc receptors were probably 
not a  factor in the uptake of aaH by lymphoid cells. The specificity of the binding 
activity was further demonstrated by the finding that excess unlabeled aaH blocked JOHN  D.  LAMBRIS AND GORDON  D.  ROSS 
TABLE  I 
Binding of 12Sl-labeled aaH to Lymphocytes and EC3 
1403 
Cell type 
[125I]aotH cpm bound in presence of  12Si.nonim. 
Buffer  Excess unla-  1.0 mg/ml  mune IgG cpm  bound in buffer  beted aaH  factor H 
B celllines 
R~i  1,020  80  75  95 
BF  1,565  120  130  150 
T cell line 
HSB  125  110  105  150 
E  360  295  299  306 
EC3b  3,250  400  395  340 
EC3d  290  250  265  275 
TABLE II 
Inhibition of the Binding of all-labeled Factor H  ([all]H) to B Cells and 
EC3b by aaH 
[SH]H cpm bound 
Pretreatment of cells 
Raji  BF  EC3b 
Buffer  6,555  3,150  8,250 
aaH*  500  325  2,501 
1,000-fold excess unlabeled H  456  134  2,457 
Sheep IgG-anti-C3b  6,600  3,045  ND$ 
* Purified by absorption and elution from C3-agarose. 
:]: Not done because anti-C3b agglutinated the EC3b. 
the uptake  of [125I]aaH.  Thus,  the aaH  had  a  binding activity that  was  similar to 
factor  H  in  that  both  aaH  and  H  bound  to  B  cells and  to  EC3b.  In  addition,  a 
common binding site for H  and aaH  was suggested by the finding that  B  cells and 
EC3b did not bind [l~SI]aaH in the presence of 1.0 mg/ml of factor H  (Table I). 
To determine whether the aaH contained two distinct antibodies that were specific 
for  either  anti-H  (anti-idiotype)  or  for  C3b  (anti-C3b),  200  mg  of the  aaH  was 
absorbed  in  succession  with  nonimmune  goat  IgG-agarose and  either  goat-anti-H- 
agarose or C3-agarose. Samples of the absorbed aaH were then labeled with 125I and 
analyzed for cell-binding activity. Absorption with  goat-anti-H-agarose removed all 
B  cell- and EC3b-specific binding activity, and, likewise, absorption with C3-agarose 
removed all B  cell-specific binding activity along with EC3b-binding activity. Only 
1 mg of bound  IgG was recovered after 4  M  guanidine elution of either the anti-H- 
agarose or the C3-agarose. Finally, when  the two different eluted IgG fractions were 
labeled with  125I, both  bound  to  B  cells and  to  EC3b  in  an  apparently  identical 
manner,  and,  in addition, the antibody eluted from C3-agarose bound to goat-anti- 
H-agarose  (data not  shown).  It was concluded  that  probably a  single anti-idiotype 
contained in the aaH reacted with both B  cells and C3b. 
To determine whether aaH blocked the binding of H  to B cell H  receptors, B cells 
were treated with either pure aaH or H  and then tested for their ability to bind 3H- 
labeled H  (Table II).  Both  the aaH  (100  #g/ml)  and  a  1,000-fold  molar excess of 1404  CHARACTERIZATION  OF  THE  LYMPHOCYTE  FACTOR  H  RECEPTOR 
unlabeled  H  blocked the uptake of [3H]H onto either Raji or BF cells. In addition, 
aaH also blocked the uptake of [3H]H onto EC3b.  Because of this finding,  a  sheep 
IgG anti-C3b was compared with the aaH for its ability to block the uptake of [3H]H 
onto B cells.  Treatment of B cells with l0 mg/ml of the sheep anti-C3b, which had an 
EC3b  agglutinating  titer  of  1,600,  had  no  effect  on  the  uptake  of  [3H]H  onto 
membrane H  receptors (Table II). 
Factor H-like Activity ofaaH.  Because the purified aaH resembled factor H  in its 
binding specificity for C3b and B cell H  receptors, aaH was examined for its ability 
to substitute  for factor H  in  functions  that  are characteristic  of factor H.  Purified 
aaH was found to function with factor I as a cofactor for cleavage of fluid-phase C3b 
and as a  potentiator for cleavage of bound C3b  (Fig.  1 and Table III). However, on 
a  weight  ratio comparison, C3-agarose affinity-purified aaH  had  only 0.1%  of the 
activity of purified factor H. With both fluid-phase [3H]C3b (Fig.  1)  and EC3b[3H] 
(data not shown), only small amounts of iC3b were detected by SDS-PAGE analysis 
after aaH and I treatment. When H  was used rather than aaH, I treatment resulted 
in complete conversion of C3b to iC3b (Fig.  1). The factor H-like activity of the aaH 
with I and bound C3b was more easily demonstrated by the Raji rosette test that is 
sensitive to very small amounts of bound iC3b (3)  (Table III). 
Because the binding of factor H  to B cell H  receptors had previously been shown 
to stimulate the release of B cell endogenous factor I (3), aaH was tested for its ability 
to trigger I release from Raji B cells (Table IV). After treatment of B cells with either 
purified aaH or H, the cells were pelleted by centrifugation, and the harvested cell- 
10 
,,I t 
i  i  i  i  i 
MIGRATION  (cm) 
FTG.  1.  Factor I cofactor activity ofaaH vs. factor H  in the cleavage of fluid-phase [3H]C3b. After 
incubation of [aH]C3b for 60 rain at 37°C with either H plus [ or aaH plus I, samples were analyzed 
by SDS-PAGE, fluorograpby, and laser densitometric scanning of x-ray film bands. The molecular 
weight  of each  gel band  was  determined  from  its mobility  relative  to  known  molecular weight 
markers run in parallel gel tracks. [3H]C3b treated with H  plus I (upper panel) was fully converted 
into  iC3b,  as  indicated  by  the  complete  absence of intact  C3b  a-chains  (115,000  Mr)  and  the 
appearance of the two characteristic iC3b a-chain fragments (67,000 and 43,000 Mr). By contrast, 
treatment of [aH]C3b with aaH plus I  (lower panel) resulted in conversion of only small amounts 
of C3b into iC3b. No iC3b was detected in controls in which [3H]C3b was treated with H, aaH, or 
I, individually (data not shown). JOHN  D.  LAMBRIS AND GORDON  D.  ROSS 
TABLE III 
Potentiation of Factor I Cleavage of Bound C3b into iC3b by Factor H or aaH 
Treatment of EC3b 10 min, 37°C  Raji rosettes with 
treated EC3b* 
% 
Buffer  0 
Factor H:~  0 
Limiting factor I  20 
Limiting factor I and factor H  99 
aaH§  0 
Limiting factor I and aaH  90 
Limiting factor I and nonimmune IgG  18 
* Rosette assay performed in BDVEA buffer that inhibits factor I release from 
Raji cells (3). 
:~ Factor H, 40/~g/ml. 
§ aaH, 140/zg/ml,  purified by elution from C3-agarose. 
TABLE IV 
Stimulation of B Cell Release of Factor I by Factor H or aaH 
1405 
Factor I activity of 
harvested  B cell su-  B cell treatment 1 h,  Addition to B cell supernatant 
37°C  harvested  after treatment  pernatant as deter- 
mined by Raji cell 
rosette assay* 
% rosettes 
Buffer  Factor H~:  0 
Factor H:]:  Buffer  58 
Factor H  Anti-factor I  0 
aaH§  Factor H  60 
aaH  Factor H and anti-factor I  0 
Nonimmune IgGIL  Factor H  0 
Fab anti-C3c 11  Factor H  0 
* Rosette assay performed  in BDVEA buffer that inhibits H receptor-mediated  Raji 
cell release of factor I (3). 
:[: Factor H concentration, 30 #g/ml. 
~  urified anti-idiotype eluted from goat anti-H-agarose,  300/zg/ml. 
Nonimmune IgG, 300 p.g/ml; Fab anti-C3c, 1.0 mg/ml. 
free supernatant fluid was examined for I  activity. The presence of small amounts of 
I  was  indicated  by the  anti-I-inhibitable conversion of Raji  rosette-negative  EC3b 
into  Raji  rosette-positive  EC3bi  (3).  Factor  I  release  was  not  detected  with  B  cells 
treated with either nonimmune  rabbit IgG or rabbit Fab anti-C3c. It was not possible 
to  use  the  sheep  IgG  anti-C3b  in  this  assay,  as  it  agglutinated the  EC3b  indicator 
cells. 
Molecular  Weight  Analysis  of the  B  Cell  Proteins  That  Bind  to  Either  aaH  or  Factor 
H.  After intrinsic [3H]leucine labeling of Raji cell or BF cell  proteins, each  B  cell 
type  was  solubilized with  NP-40  and  immunoprecipitated  with  purified  aaH  and 
anti-rabbit  IgG-agarose  beads.  Analysis of the  all-labeled  immune  precipitates  by 
SDS-PAGE  revealed  two  proteins  of  100,000  Mr  and  50,000  Mr  without  reduction 
and  a  single protein  band  of 50,000  Mr with complete  reduction of disulfide bonds 
(Fig.  2). A  similar protein molecular weight profile was obtained with actH-immune 
precipitation of either Raji or BF B-cell lines, whereas no SDS-PAGE protein bands 1406  CHARACTERIZATION  OF THE  LYMPHOCYTE  FACTOR  H  RECEPTOR 
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FIG.  2.  aaH immunoprecipitation and SDS-PAGE analysis of [3H]leucine intrinsically labeled BF 
B-type lymphoblastoid  cells. NP-40  solubilized cells were precipitated with aaH  and goat-anti- 
rabbit-lgG-agarose beads, and then the immune precipitates were analyzed by SDS-PAGE. The 
positions of known molecular weight  markers run  in  parallel gel  tracks is indicated  by  arrows 
(~-galactosidase,  116,500 M+; phosphorylase b, 94,000 Mr; BSA, 68,000 Mr; and ovalbumin, 43,000 
M,). 
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FIe.  3.  SDS-PAGE  analysis of [aH]leucine intrinsically labeled Raji cell  proteins absorbed and 
eluted from H-agarose. See legend to Fig. 2 for molecular weight markers. 
were  observed  with  either  aaH  immune  precipitates  from  [3H]leucine  intrinsically 
labeled HSB T  cells or nonimmune IgG precipitates of labeled  Raji or BF cells. 
Experiments  were  also  undertaken  to  characterize  the  B  cell  proteins  that  had 
factor H-binding  (H receptor)  activity.  Spent  culture media from [3H]leucine  intrin- 
sically labeled  Raji cells was chromatographed  on  a  column  of H-agarose,  and  then 
the  bound  proteins  were eluted  with  0.5%  NP-40  in  0.5  M  NaCI  and  analyzed  by 
SDS-PAGE.  As  shown  in  Fig.  3,  a  similar  protein  molecular  weight  profile  was 
obtained  as  with  aaH  immune precipitation  (Fig.  2).  No comparable  radioactive  B JOHN  D.  LAMBRIS  AND  GORDON  D.  ROSS  1407 
cell  proteins  were detected  when  the control  eluate of a  BSA-agarose column  was 
analyzed by the same procedure. When purified C3b was electrophoresed in parallel 
gel tracks, its known  (20)  115,000  Mr a-chain and  75,000 Mr fl-chain structure was 
confirmed to be distinct  from the B cell proteins that bound to aaH or H. 
Discussion 
aaH was shown to bind to both B lymphocyte membrane factor H  receptors and 
C3b. The aaH blocked the uptake of H  onto B cells and triggered B cells to release 
factor I in the same manner as did purified H. aaH also had H-like activity with C3b 
in  that  it served as a  cofactor for I  cleavage of fluid-phase C3b  and  potentiated  I 
cleavage of bound C3b. SDS-PAGE analysis of B cell proteins, either immunoprecip- 
itated  with  aaH  or isolated  by affinity chromatography on  H-agarose,  revealed  a 
similar protein molecular weight profile that probably represents the membrane H 
receptor. 
The binding of [125I]aaH to both B cells and EC3b was preliminary evidence for 
the H  receptor specificity of aaH, as both B cells and C3b have H-binding sites. The 
finding that aaH blocked [3H]H binding to B cells and EC3b and, conversely, that H 
similarly blocked the binding of aaH,  indicated  that aaH bound at or near the H- 
binding site of B ceils and C3b. Further evidence for the H-binding site specificity of 
aaH was the observation that aaH had the ability to substitute  for H  in  reactions 
that are characteristic of H. Both purified H  and aaH triggered B cells to release I. 
In addition, aaH not only bound to C3b, but it also functioned with I in the cleavage 
of C3b into iC3b. These same H-like activities could not be demonstrated with sheep 
IgG anti-C3b or rabbit Fab-anti-C3c. However, aaH had only 0.1% of the activity of 
H  in I cleavage of C3b into iC3b. This finding suggests that H  function with I may 
depend on H  interaction with I as well as with C3b and that aaH may differ from H 
in that it binds only to C3b and does not also interact with I. Other studies  (8) have 
previously suggested the existence of a  trimolecular complex of C3b,  H, and I  that 
preceded  iC3b  formation.  However, factor I  also has been  shown  to bind  to C3b- 
agarose (3) and EC3b (8) independently of H, suggesting that H  binding to C3b may 
only serve to expose the I-cleavage site in C3b and that H  itself may not bind to I. If 
this were the case, then perhaps aaH binds to the H-binding site of C3b and either 
does not expose the I-cleavage site or partially covers this site. 
The finding that the aaH IgG fraction contained antibodies that were specific for 
C3b as well as for B cell H  receptors was not unexpected. However, it was anticipated 
that the antibodies that were specific for the H-binding site of C3b would be distinct 
from those antibodies that were specific for the binding site of the H  receptor. All B 
cell-binding activity of the aaH IgG fraction was absorbed and subsequently eluted 
from C3-agarose. This finding apparently indicates that C3b and H  receptors have a 
similar H-binding site and, thus, probably bind to the same site in the H  molecule. 
However, if this is the case, it is not clear how complexes bearing C3b,H could trigger 
H  receptors  (3),  as  it  would  be expected  that  the  receptor-binding  site  in  the  H 
molecule would  be occupied  by C3b.  This  same paradox  does  not  exist  with  Clq 
receptors.  Clq receptors have been shown  to be specific for the collagen portion of 
Clq, whereas  immunoglobulin  Fc binds to the globulin  portion of Clq.  This allows 
Clq-bearing IgG or IgM aggregates to bind to Clq receptors (21). By comparison, for 
C3b,H  complexes to  trigger H  receptors, the  H  molecule would  either  have to  be 1408  CHARACTERIZATION OF THE LYMPHOCYTE FACTOR H  RECEPTOR 
bivalent  in  identical  receptor-binding  sites  or  be  able  to  transfer  from  C3b  to  H 
receptors in an activated form. No evidence has ever been presented for an activated 
form of factor H. However, because purified H  has been noted to have a tendency to 
aggregate with itself (3, and S. Ruddy, personnel communication), it is possible that 
H  interaction  with  bound  C3b  might  lead  to  similar  H  aggregation,  so that  C3b 
complexes might present H  dimers or larger H aggregates to cells bearing H  receptors. 
Alternatively, even though  H  has been  thought  to be monovalent  in  C3b  binding 
sites (17, 22), some of the data concerning the uptake of 125I-factor H  by EAC 14°xy23b 
(22)  vs.  EC3b  (17)  could  be interpreted  as  indicating  that  H  was  bivalent.  Using 
EAC 14°xy23b that contained 64,000 bound C3b molecules per cell, Conrad et at. (22) 
measured  an  uptake of only 0.5  H  molecules per C3b  molecule and an  H  to C3b 
affinity  constant  of  109  L/M.  By  contrast,  Kazatchkine  et  al.  (17),  using  EC3b 
containing 30,000 C3b per cell generated with an unstabilized convertase (C3b,Bb), 
observed an uptake of 1.0  H  per C3b with an affinity constant  of 1 ×  10  -7 M  (107 
L/M).  C3  fixation  onto  EAC14°xY2  is  believed  to  generate  large  dense  clusters  of 
bound C3b molecules surrounding individual C4°xY2 sites, because the half-life of the 
C4°xY2 enzyme is  150  min  at  32°C  (23).  On  the  other  hand,  because  the  bound 
C3b,Bb enzyme has a half-life of only 4 min at 30°C  (24), it would be expected that 
only  small  numbers  of C3b  molecules  would  be  fixed  by  individual  unstabilized 
enzyme sites and  that  resulting C3b clusters would  be small.  If H  were bivalent  in 
C3b  binding  sites,  then  a  single  H  molecule  might  be  able  to  bridge  two  C3b 
molecules contained in a dense C3b cluster. This would result in an H  binding of 0.5 
molecules per C3b, and the cooperativity provided by dual-point attachment of H  to 
two C3b molecules would greatly increase the H  affinity constant over that observed 
with single-point H  attachment to individual more widely spaced C3b molecules. 
Because all of the various findings indicated that aaH was probably specific for H 
receptors,  aaH  immunoprecipitation  was  used  in  parallel  with  H-agarose affinity 
chromatography to characterize the molecular weight of B cell H  receptors. Analysis 
by SDS-PAGE revealed two proteins of 100,000  and  50,000  Mr without  reduction, 
and a  single protein band at 50,000 Mr after complete reduction of disulfide bonds. 
From  this  data  it  appears  possible that  the  membrane  H  receptor  may consist  of 
50,000-Mr subunits, with the disulfide-linked  subunits  of the unreduced  100,000-Mr 
component  possibly  being  distinct  from  the  unreduced  50,000-Mr  component.  In 
future studies, larger quantities  of H  receptor will be isolated by H-agarose affinity 
chromatography  and  used  for  a  more complete  structural  characterization  of the 
receptor. Of particular interest will be determination of the carbohydrate composition 
of the receptor and the contribution of sugars to the binding site. A  large portion of 
the structure of factor H  is believed to be carbohydrate (1). 
The main use planned for the isolated H  receptor is to produce a polyclonal anti-H 
receptor antibody that could be converted into F(ab')2 and Fab' fragments. The very 
small quantities of aaH  available precluded  their use in generation of such pepsin- 
derived  fragments.  If both  F(ab')2  and  Fab'  anti-H  receptor  bound  to  B  cell  H 
receptors, but only the F(ab')2 and not the Fab' antibody triggered I release, it would 
indicate that receptor cross-linkage by a bivalent H-ligand was probably required for 
triggering of receptor function. Such an F(ab')2 anti-H receptor, as well as purified H 
aggregates, would also be valuable specific probes of lymphocyte H receptor-mediated 
functions other than I release. It is noted with considerable interest  that  Hammann JOHN D.  LAMBRIS AND GORDON  D.  ROSS  1409 
et al.  (4)  recently reported that purified human H  triggers mouse spleen cell blasto- 
genesis. 
Summary 
Antibody  to  the  binding  site  (idiotype)  of  anti-factor  H  was  shown  to  have 
specificity for both B lymphocyte membrane H  receptors and C3b. Goat F(ab')2 anti- 
human H  was purified by absorption and elution from H  agarose and used for rabbit 
immunization to produce anti-anti-H (aaH). After absorption with nonimmune goat 
IgG, a2~I-labeled aaH bound to B lymphocytes and to sheep erythrocytes coated with 
C3b  (EC3b)  but  did  not  bind  to T  lymphocytes or to EC3d.  All  B  cell- and C3b- 
specific activities of the aaH were removed and subsequently recovered by absorption 
and  elution  of the  antibody  from  either  C3-agarose  or  goat-anti-H-agarose.  This 
indicated that the aaH probably recognized a single common antigenic structure that 
was shared  by anti-H,  C3b,  and  the  membranes of B  cells.  Affinity-purified aaH 
resembled  H  in  that  it  bound  to  B  cells,  blocked  the  uptake of H  onto  B  cell  H 
receptors, and triggered B  cells to release endogenous factor I  (C3b inactivator).  In 
addition, aaH functioned with factor I as either a cofactor for cleavage of fluid-phase 
C3b or a  potentiator for cleavage of bound C3b. This same spectrum of C3 binding 
functions could not be demonstrated with either sheep anti-C3b or rabbit-anti-C3c. 
Analysis  by  sodium  dodecyl  sulfate-polyacrylamide  get  electrophoresis  of  the 
[3H]leucine intrinsically labeled B cell proteins reactive with the purified aaH revealed 
proteins of 100,000 Mr and 50,000 Mr without reduction, and after complete reduction 
of disulfide bonds, a  single protein band of 50,000 Mr. This same protein molecular 
weight profile was also demonstrated with labeled B cell proteins that were absorbed 
and  eluted  from  H-agarose.  Thus,  aaH  is  apparently  specific  for  both  B  cell  H 
receptors and C3b.  However, because parallel analysis of C3b confirmed its known 
115,000-  and  75,000-Mr polypeptide chain structure,  the H  receptor is probably not 
C3b and shares only the structure of the H  binding site with C3b. 
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